Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the week of 23rd March - 30th March Rocket Pharma ( FDA, Approval ) Rocket Pharma obtains FDA approval for KRESLADI, an autologous hematopoietic stem cell-based gene therapy to treat pediatric patients with severe leukocyte adhesion deficiency-I Denali Therapeutics ( FDA, Approval ) FDA grants approval to Denali Therapeutics' AVLAYAH, an enzyme replacement therapy to treat the neurologic manifestations of Hunter syndrome Corcept Therapeutics ( FDA, Approval ) Corcept Therapeutics gets FDA approval for LIFYORLI plus nab-paclitaxel to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior systemic treatment regimens Gedeon Richter ( EU, Approval ) EC grants approval to Gedeon Richter's FYLREVY as a hormone replacement therapy for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 23rd March 2026- 30th March 2026 in the world of pharma and healthcare

April 1, 2026

Highlights from the Week of 16th March 2026 - 23rd March 2026 ( FDA, Approval ) FDA grants approval to Rhythm Pharmaceuticals' IMCIVREE as a label expansion to treat acquired hypothalamic obesity in patients aged 4 years and older ( FDA, Approval ) Novo Nordisk's WEGOVY HD 7.2 mg gains FDA approval to reduce excess body weight and maintain long‑term weight reduction, based on results from the STEP UP trial ( FDA, Approval ) Johnson & Johnson receives FDA approval for ICOTYDE, an IL-23R-targeted oral peptide for treating moderate-to-severe plaque psoriasis ( FDA, Approval ) FDA approves GSK's LYNAVOY, an IBAT inhibitor, to treat cholestatic pruritus in patients with primary biliary cholangitis Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 16th March 2026 – 23rd March 2026 in the world of pharma and healthcare!

March 24, 2026

VYUHPHARMA Highlights from the Week of 9th February - 16th February MERCK 百奥泰 BIO-THERA AMGEN FDA approves Merck's KEYTRUDA and KEYTRUDA QLEX for certain patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens European Commission grants marketing authorization for Bio-Thera's GOTENFIA, a biosimilar referencing SIMPONI, for the treatment of various types of arthritis European Commission approves Amgen's UPLIZNA for the treatment of adult patients with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive (FDA, Approval) (EU, Approval) (EU, Approval) Pg 1/4 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 9th February – 16th February in the world of pharma and healthcare! 🗞️👀

February 18, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

INVESTOR CALENDER OF THE WEEK March 24,2026 To March 26,2026 BNP Paribas Exane Healthcare Conference March 24 Goldman Sachs Biopharma Innovation Summit March 25 March 26 All logos and trademarks remain the intellectual properties of their respective owners

Attention Stay up to date with the latest investor calls by checking out our calendar for the week of March 24,2026 To March 26,2026

March 24, 2026

INVESTOR CALENDER OF THE WEEK 18-Feb-2026 Citi's 2026 Virtual Oncology leadership Summit Fourth-Quarter and Full-Year 2025 Earnings Presentation Feb 18 Feb 18 AMGEN BAUSCH Health Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of 18- Feb-2026💻

February 18, 2026

Q4 2025 Earning conference Call Feb 10,2026 To Feb 13,2026 Feb 10 Feb 12 Feb 13 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Feb 10,2026 To Feb 13,2026💻

February 9, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

So near, yet so far – 26 years of innovation and discovery in the NMOSD space

April 1, 2026

As we come to the end of the NMOSD awareness month, in this article, we will look at the journey so far for patients, caregivers,

« Previous Page1 Page2 Page3 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message